Skip to main content

07-17-2018 | Obesity | Review | Article

Weight Management in Patients with Type 2 Diabetes: a Multidisciplinary Real-world Approach

Journal: Current Diabetes Reports

Authors: Osama Hamdy, Sahar Ashrafzadeh, Adham Mottalib

Publisher: Springer US


Purpose of Review

Obesity and type 2 diabetes (T2D) are closely linked metabolic diseases. Most individuals with T2D are overweight or obese, which raises their cardiovascular risk. The etiology of both diseases is multifaceted, thus requiring a multidisciplinary approach to control them. This review describes the most effective multidisciplinary approach to weight management in patients with T2D in real-world clinical practice.

Recent Findings

Weight management programs in real-world clinical settings lead to long-term weight loss for up to 5 years.


Multidisciplinary approach to manage obesity and T2D through weight reduction is feasible in real-world clinical practice and is recommended as part of the treatment plan for patients with T2D who are overweight or obese. Recent data demonstrates that multidisciplinary approach to weight management in patients with T2D results in long-term weight loss and is associated with improved cardiovascular risk factors.
Caballero B. The global epidemic of obesity: an overview. Epidemiol Rev. 2007;29(1):1–5.CrossRefPubMed
Herman WH, Zimmet P. Type 2 diabetes: an epidemic requiring global attention and urgent action. Diabetes Care. 2012;35(5):943–4. https://​doi.​org/​10.​2337/​dc12-0298.CrossRefPubMedPubMedCentral
Prevention CfDCa. Prevalence of overweight and obesity among adults with diagnosed diabetes—United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep. 2004;53(45):1066–8.
Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JP, Pinkney JH. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006;82(966):280–4. https://​doi.​org/​10.​1136/​pmj.​2005.​039032.CrossRefPubMedPubMedCentral
• Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res. 2016;118(11):1723–35. https://​doi.​org/​10.​1161/​circresaha.​115.​306825. This study describes trends in the current obesity and diabetes epidemics in the USA and their associated health complications. CrossRefPubMedPubMedCentral
Holmes MV, Pulit SL, Lindgren CM. Genetic and epigenetic studies of adiposity and cardiometabolic disease. Genome Med. 2017;9(1):82. https://​doi.​org/​10.​1186/​s13073-017-0474-5.​ CrossRefPubMedPubMedCentral
ADA. Lifestyle management. Sec. 4. In Standards of Medical Care in Diabetes—2017. Diabetes Care. 2017;40(Supplement 1):S33–43. https://​doi.​org/​10.​2337/​dc17-S007.CrossRef
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary. Endocr Pract. 2018;24(1):91–120. https://​doi.​org/​10.​4158/​cs-2017-0153.CrossRefPubMed
Chin MH, Cook S, Jin L, Drum ML, Harrison JF, Koppert J, et al. Barriers to providing diabetes care in Community Health Centers. Diabetes Care. 2001;24(2):268–74. https://​doi.​org/​10.​2337/​diacare.​24.​2.​268.CrossRefPubMed
Wens J, Vermeire E, Royen PV, Sabbe B, Denekens JGP. ‘Perspectives of type 2 diabetes patients’ adherence to treatment: a qualitative analysis of barriers and solutions. BMC Fam Pract. 2005;6(1):20. https://​doi.​org/​10.​1186/​1471-2296-6-20.​ CrossRefPubMedPubMedCentral
Jansink R, Braspenning J, van der Weijden T, Elwyn G, Grol R. Primary care nurses struggle with lifestyle counseling in diabetes care: a qualitative analysis. BMC Fam Pract. 2010;11(1):41. https://​doi.​org/​10.​1186/​1471-2296-11-41.​ CrossRefPubMedPubMedCentral
Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf. 2009;8(5):573–84. https://​doi.​org/​10.​1517/​1474033090308172​5.CrossRefPubMed
Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–6. https://​doi.​org/​10.​1038/​nature05482.CrossRefPubMed
Hamdy O, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care. 2003;26(7):2119–25.CrossRefPubMed
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. https://​doi.​org/​10.​1056/​NEJMoa012512.​ CrossRefPubMed
Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54. https://​doi.​org/​10.​1056/​NEJMoa1212914.​ CrossRefPubMed
•• Hamdy O, Mottalib A, Morsi A, El-Sayed N, Goebel-Fabbri A, Arathuzik G, et al. Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with diabetes in real-world clinical practice: a 5-year longitudinal study. BMJ Open Diabetes Res Care. 2017;5(1):e000259. This study reported that long-term weight loss can be achieved by patients with diabetes and obesity through a lifestyle intervention program in real-world clinical practice. CrossRefPubMedPubMedCentral
Yumuk V, Fruhbeck G, Oppert JM, Woodward E, Toplak H. An EASO position statement on multidisciplinary obesity management in adults. Obesity facts. 2014;7(2):96–101. https://​doi.​org/​10.​1159/​000362191.CrossRefPubMedPubMedCentral
Phelan S, Wyatt HR, Hill JO, Wing RR. Are the eating and exercise habits of successful weight losers changing? Obesity (Silver Spring, Md). 2006;14(4):710–6. https://​doi.​org/​10.​1038/​oby.​2006.​81.​ CrossRef
Thomas JG, Bond DS, Phelan S, Hill JO, Wing RR. Weight-loss maintenance for 10 years in the National Weight Control Registry. Am J Prev Med. 2014;46(1):17–23. https://​doi.​org/​10.​1016/​j.​amepre.​2013.​08.​019.CrossRefPubMed
Montesi L, El Ghoch M, Brodosi L, Calugi S, Marchesini G, Dalle Grave R. Long-term weight loss maintenance for obesity: a multidisciplinary approach. Diabetes, metabolic syndrome and obesity : targets and therapy 2016;9:37–46. doi:https://​doi.​org/​10.​2147/​dmso.​s89836.
Hamdy O, Carver C. The Why WAIT program: improving clinical outcomes through weight management in type 2 diabetes. Curr Diabetes Rep. 2008;8(5):413–20.CrossRef
Jennings A, Hughes CA, Kumaravel B, Bachmann MO, Steel N, Capehorn M, et al. Evaluation of a multidisciplinary Tier 3 weight management service for adults with morbid obesity, or obesity and comorbidities, based in primary care. Clinical obesity. 2014;4(5):254–66. https://​doi.​org/​10.​1111/​cob.​12066.CrossRefPubMedPubMedCentral
Lih A, Pereira L, Bishay RH, Zang J, Omari A, Atlantis E, et al. A novel multidisciplinary intervention for long-term weight loss and glycaemic control in obese patients with diabetes. J Diabetes Res. 2015;2015:729567. https://​doi.​org/​10.​1155/​2015/​729567.CrossRefPubMedPubMedCentral
Romanova M, Liang LJ, Deng ML, Li Z, Heber D. Effectiveness of the MOVE! Multidisciplinary weight loss program for veterans in Los Angeles. Prev Chron Dis. 2013;10:E112. https://​doi.​org/​10.​5888/​pcd10.​120325.CrossRef
Mauro M, Taylor V, Wharton S, Sharma AM. Barriers to obesity treatment. Eur J Int Med. 2008;19(3):173–80. https://​doi.​org/​10.​1016/​j.​ejim.​2007.​09.​011.CrossRef
Mordes JP, Liu C, Xu S. Medications for weight loss. Current opinion in endocrinology, diabetes, and obesity 2015;22(2):91–7. doi:https://​doi.​org/​10.​1097/​med.​0000000000000140​.
Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327(20):1426–33. https://​doi.​org/​10.​1056/​nejm199211123272​005.​ CrossRefPubMed
Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet (London, England). 2012;379(9825):1489–97. https://​doi.​org/​10.​1016/​s0140-6736(12)60204-9.CrossRef
Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98(3):1154–62. https://​doi.​org/​10.​1210/​jc.​2012-3249.CrossRefPubMedPubMedCentral
Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38(12):2217–25. https://​doi.​org/​10.​2337/​dc15-0249.CrossRefPubMed
Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract. 2005;11(1):11–7. https://​doi.​org/​10.​4158/​ep.​11.​1.​11.​ CrossRefPubMed
Food and Drug Administration. FIASP® (insulin aspart injection) [label]. Novo Nordisk A/S, Bagsvaerd, Denmark. 2017.
Food and Drug Administration. APIDRA® (insulin glulisine [rDNA origin] injection) [label]. Sanofi-Aventis U.S. LLC, Bridgewater, NJ. 2015.
Joslin EP. The treatment of diabetes mellitus. Can Med Assoc J. 1916;6(8):673–84.PubMedPubMedCentral
Allen FM, Stillman E, Fitz R. Total dietary regulation in the treatment of diabetes. vol 11. Rockefeller Institute for Medical Research; 1919.
Mottalib A, Salsberg V, Mohd-Yusof B-N, Mohamed W, Carolan P, Pober DM, et al. Effects of nutrition therapy on HbA1c and cardiovascular disease risk factors in overweight and obese patients with type 2 diabetes. Nutr J. 2018;17(1):42. https://​doi.​org/​10.​1186/​s12937-018-0351-0.CrossRefPubMedPubMedCentral
Eight-year weight losses with an intensive lifestyle intervention: The Look AHEAD Research Group. Obesity (Silver Spring, Md). 2014;22(1):5–13. doi:https://​doi.​org/​10.​1002/​oby.​20662
Wadden TA, West DS, Delahanty L, Jakicic J, Rejeski J, Williamson D, et al. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring, Md). 2006;14(5):737–52. https://​doi.​org/​10.​1038/​oby.​2006.​84.​ CrossRef
Giusti J, Rizzotto JA. Interpreting the Joslin Diabetes Center and Joslin Clinic Clinical Nutrition Guideline for overweight and obese adults with type 2 diabetes. Curr Diabetes Rep. 2006;6(5):405–8.CrossRef
Campbell A. Tackling “diabesity” head-on. Joslin Diabetes Center’s new nutrition guideline. Diabetes self-management 2005;22(6):40, 2–4.
Hamdy O, Horton ES. Protein content in diabetes nutrition plan. Curr Diabetes Rep. 2011;11(2):111–9. https://​doi.​org/​10.​1007/​s11892-010-0171-x.CrossRef
Wadden TA, Neiberg RH, Wing RR, Clark JM, Delahanty LM, Hill JO, Krakoff J, Otto A, Ryan DH, Vitolins MZ, Look AHEAD Research Group Four-year weight losses in the look AHEAD study: factors associated with long-term success. Obesity (Silver Spring, Md). 2011;19(10):1987–1998. doi:https://​doi.​org/​10.​1038/​oby.​2011.​230.
Cheskin LJ, Mitchell AM, Jhaveri AD, Mitola AH, Davis LM, Lewis RA, et al. Efficacy of meal replacements versus a standard food-based diet for weight loss in type 2 diabetes: a controlled clinical trial. Diabetes Educ. 2008;34(1):118–27. https://​doi.​org/​10.​1177/​0145721707312463​.CrossRefPubMed
Heymsfield S, Van Mierlo C, Van der Knaap H, Heo M, Frier H. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes. 2003;27(5):537–49.CrossRef
Li D, Zhang P, Guo H, Ling W. Taking a low glycemic index multi-nutrient supplement as breakfast improves glycemic control in patients with type 2 diabetes mellitus: a randomized controlled trial. Nutrients. 2014;6(12):5740–55. https://​doi.​org/​10.​3390/​nu6125740.CrossRefPubMedPubMedCentral
Hamdy O, Zwiefelhofer D. Weight management using a meal replacement strategy in type 2 diabetes. Curr Diabetes Rep. 2010;10(2):159–64. https://​doi.​org/​10.​1007/​s11892-010-0103-9.CrossRef
Mottalib A, Mohd-Yusof BN, Shehabeldin M, Pober DM, Mitri J, Hamdy O. Impact of diabetes-specific nutritional formulas versus oatmeal on postprandial glucose, insulin, GLP-1 and postprandial Lipidemia. Nutrients. 2016;8(7):443. https://​doi.​org/​10.​3390/​nu8070443.CrossRefPubMedCentral
Capodaglio P, De Souza SA, Parisio C, Precilios H, Vismara L, Cimolin V, et al. Reference values for the 6-min walking test in obese subjects. Disabil Rehabil. 2013;35(14):1199–203. https://​doi.​org/​10.​3109/​09638288.​2012.​726313.CrossRefPubMed
Swift DL, Johannsen NM, Lavie CJ, Earnest CP, Church TS. The role of exercise and physical activity in weight loss and maintenance. Prog Cardiovasc Dis. 2014;56(4):441–7. https://​doi.​org/​10.​1016/​j.​pcad.​2013.​09.​012.CrossRefPubMed
Umegaki H. Sarcopenia and diabetes: hyperglycemia is a risk factor for age-associated muscle mass and functional reduction. J Diabetes Investig. 2015;6(6):623–4. https://​doi.​org/​10.​1111/​jdi.​12365.CrossRefPubMedPubMedCentral
Jefferis BJ, Parsons TJ, Sartini C, Ash S, Lennon LT, Wannamethee SG, et al. Does duration of physical activity bouts matter for adiposity and metabolic syndrome? A cross-sectional study of older British men. Int J Behav Nutr Phys Act. 2016;13(36):36. https://​doi.​org/​10.​1186/​s12966-016-0361-2.​ CrossRefPubMedPubMedCentral
Glazer NL, Lyass A, Esliger DW, Blease SJ, Freedson PS, Massaro JM, et al. Sustained and shorter bouts of physical activity are related to cardiovascular health. Med Sci Sports Exerc. 2013;45(1):109–15. https://​doi.​org/​10.​1249/​MSS.​0b013e31826beae5​.CrossRefPubMedPubMedCentral
Wadden TA, Stunkard AJ. Handbook of obesity treatment: Guilford Press; 2002.
The Look AHEAD Research Group: description of lifestyle intervention. Diabetes Care. 2002;25(12):2165–71.
Nikolaou CK, Lean MEJ. Mobile applications for obesity and weight management: current market characteristics. Int J Obes. 2016;41(1):200–2. https://​doi.​org/​10.​1038/​ijo.​2016.​186.CrossRef
Bonn SE, Alexandrou C, Steiner KH, Wiklander K, Östenson C, Löf M, et al. App-technology to increase physical activity among patients with diabetes type 2—the DiaCert-study, a randomized controlled trial. BMC Public Health. 2018;18(1):119. https://​doi.​org/​10.​1186/​s12889-018-5026-4.CrossRefPubMedPubMedCentral
Carter MC, Burley VJ, Nykjaer C, Cade JE. Adherence to a smartphone application for weight loss compared to website and paper diary: pilot randomized controlled trial. J Med Internet Res. 2013;15(4):e32. https://​doi.​org/​10.​2196/​jmir.​2283.CrossRefPubMedPubMedCentral
Pagoto S, Schneider K, Jojic M, DeBiasse M, Mann D. Evidence-based strategies in weight-loss mobile apps. Am J Prev Med. 2013;45(5):576–82. https://​doi.​org/​10.​1016/​j.​amepre.​2013.​04.​025.CrossRefPubMed
El Khoury L, Chouillard E, Chahine E, Saikaly E, Debs T, Kassir R. Metabolic surgery and diabesity: a systematic review. Obes Surg. 2018;28:2069–77. https://​doi.​org/​10.​1007/​s11695-018-3252-6.CrossRefPubMed
Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med. 2017;376(7):641–51.CrossRefPubMedPubMedCentral
Ikramuddin S, Billington CJ, Lee W-J, Bantle JP, Thomas AJ, Connett JE, et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. Lancet Diabetes Endocrinol. 2015;3(6):413–22.CrossRefPubMedPubMedCentral
Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial–a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–34.CrossRefPubMed
Yska JP, van Roon EN, de Boer A, Leufkens HG, Wilffert B, de Heide LJ, et al. Remission of type 2 diabetes mellitus in patients after different types of bariatric surgery: a population-based cohort study in the United Kingdom. JAMA Surgery. 2015;150(12):1126–33. https://​doi.​org/​10.​1001/​jamasurg.​2015.​2398.CrossRefPubMed
Peterli R, Borbely Y, Kern B, Gass M, Peters T, Thurnheer M, et al. Early results of the Swiss Multicentre Bypass or Sleeve Study (SM-BOSS): a prospective randomized trial comparing laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass. Ann Surg. 2013;258(5):690–4; discussion 5. https://​doi.​org/​10.​1097/​SLA.​0b013e3182a67426​.CrossRefPubMedPubMedCentral
•• Patel P, Hartland A, Hollis A, Ali R, Elshaw A, Jain S, et al. Tier 3 multidisciplinary medical weight management improves outcome of Roux-en-Y gastric bypass surgery. Ann R Coll Surg Engl. 2015;97(3):235–7. https://​doi.​org/​10.​1308/​003588414x140559​25061838. This study demonstrates the benefits of a weight management program prior to gastric bypass surgery in improving weight loss outcomes in patients. CrossRefPubMedPubMedCentral
Goldfine AB, Patti ME. How common is hypoglycemia after gastric bypass? Obesity (Silver Spring, Md). 2016;24(6):1210–1. https://​doi.​org/​10.​1002/​oby.​21520.​ CrossRef
Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointest Endosc. 2013;78(3):530–5. https://​doi.​org/​10.​1016/​j.​gie.​2013.​04.​197.CrossRefPubMed
Franco JV, Ruiz PA, Palermo M, Gagner M. A review of studies comparing three laparoscopic procedures in bariatric surgery: sleeve gastrectomy, Roux-en-Y gastric bypass and adjustable gastric banding. Obes Surg. 2011;21(9):1458–68. https://​doi.​org/​10.​1007/​s11695-011-0390-5.CrossRefPubMed
Cho JM, Kim HJ, Lo Menzo E, Park S, Szomstein S, Rosenthal RJ. Effect of sleeve gastrectomy on type 2 diabetes as an alternative treatment modality to Roux-en-Y gastric bypass: systemic review and meta-analysis. Surg Obes Relat Dis. 2015;11(6):1273–80. https://​doi.​org/​10.​1016/​j.​soard.​2015.​03.​001.​ CrossRefPubMed
Ding SA, Simonson DC, Wewalka M, Halperin F, Foster K, Goebel-Fabbri A, et al. Adjustable gastric band surgery or medical management in patients with type 2 diabetes: a randomized clinical trial. J Clin Endocrinol Metab. 2015;100(7):2546–56. https://​doi.​org/​10.​1210/​jc.​2015-1443.CrossRefPubMedPubMedCentral

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »